Crabtree, G.R.: Generic signals and specific outcomes: signaling through Ca2+, calcineurin, and NF-AT. Cell 1999, 96:611–614.
Crespo, J.L., and Hall, M.N.: Elucidating TOR signaling and rapamycin action: lessons from Saccharomyces cerevisiae. Microbiol. Mol. Biol. Rev. 2002, 66:579–591.
Fleischmann, R, Kremer, J., Cush, J., Schulze-Koops, H., Connell, C.A., Bradley, J.D., Gruben, D., Wallenstein, G.V., Zwillich, S.H., Kanik, K.S. et al.: Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 2012, 367:495–507.
Pesu, M., Laurence, A., Kishore, N, Zwillich, S.H., Chan, G, and O'Shea, J.J.: Therapeutic targeting of Janus kinases. Immunol. Rev. 2008, 223:132–142.
16-4 Antibodies against cell-surface molecules can be used to eliminate lymphocyte subsets or to inhibit lymphocyte function.
Graca, L., Le Moine, A., Cobbold, S.P., and Waldmann, H.: Antibody-induced transplantation tolerance: the role of dominant regulation. Immunol. Res. 2003, 28:181–191.
Nagelkerke, S.Q, and Kuijpers, T.W.: Immunomodulation by IVIg and the role of Fc-gamma receptors: classic mechanisms of action after all? Front. Immunol. 2015, 5:674.
Nagelkerke, S.Q., Dekkers, G., Kustiawan, I, van de Bovenkamp, F.S., Geissler, J., Plomp, R., Wuhrer, M., Vidarsson, G., Rispens, T., van den Berg, T.K. et al: Inhibition of FcγR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcγRIIb in human macrophages. Blood 2014, 124:3709–3718.
Waldmann, H., and Hale, G.: CAMPATH: from concept to clinic. Phil. Trans. R. Soc. Lond. B 2005, 360:1707–1711.
16-5 Antibodies can be engineered to reduce their immunogenicity in humans.
Kim, S.J., Park, Y., and Hong, H.J.: Antibody engineering for the development of therapeutic antibodies. Mol. Cell 2005, 20:17–29.
Liu, X.Y., Pop, L.M., and Vitetta, E.S.: Engineering therapeutic monoclonal antibodies. Immunol. Rev. 2008, 222:9–27.
Smith, K., Garman, L., Wrammert, J., Zheng, N.Y., Capra, J.D., Ahmed, R., and Wilson, P.C.: Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat. Protocols 2009, 4:372–384.